Tag: Eli Lilly and Co

GLP-1 drugs are changing how Americans eat. Food companies are racing to catch up

FDA approves higher dose version of weight loss drug Wegovy as Novo Nordisk tries to win back market share

Eli Lilly’s next-generation obesity drug retatrutide clears first late-stage diabetes trial

Healthy Returns: Stopping GLP-1s raises risk of heart attack, stroke and death, study says

Eli Lilly shares slide after a bearish Wall Street analyst call — here’s our view

Hims & Hers shares surge 50% after Novo Nordisk drops patent infringement case over compounded weight loss drugs

Eli Lilly launches program to help boost employer coverage of obesity drugs in U.S.

Why Novo Nordisk’s Ireland expansion is key to fighting off Eli Lilly

Here’s an update on our 4th Industrial Revolution stocks and the rest of the portfolio

Healthy Returns: What’s next for Novo Nordisk’s next-generation obesity drug CagriSema after trial miss